A federal court judge ruling leaves in place an FDA determination that shortages of the Novo Nordisk drugs Wegovy and Ozempic are resolved. Consequently, compounding pharmacies must stop making their versions of the metabolic medicines or face FDA enforcement action.
The post Novo Nordisk Notches a Court Win Against Wegovy and Ozempic Compounders appeared first on MedCity News.
